Quinapril is used to treat hypertension and lower blood pressure.
The U.S. Food and Drug Administration said Lupin Pharmaceuticals Inc. has voluntarily recalled blood pressure medicine due to its cancer risk.
The recall involves certain Quinapril tablets due to the presence of a nitrosamine impurity, N-Nitroso-Quinapri. The chemical was found in recent testing and was found to be above the acceptable daily intake level.The company said they have received no reports of any illnesses relating to the recall. It discontinued the marketing of Quinapril tablets in September 2022.
Lupin Pharmaceuticals said it is working to obtain all the recalled medicine from wholesalers, distributors, drug chains, mail-order pharmacies and supermarkets. This story was reported from Los Angeles.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Blood pressure tablets recalled over potential cancer risk, FDA announcesFour lots of the blood pressure medication Quinapril were voluntarily recalled over concerns it could increase the risk of cancer, the Food and Drug Administration said.
Read more »
Blood pressure tablets recalled over potential cancer risk, FDA announcesThe FDA announced the second recall in months of blood-pressure medication over an elevated cancer risk. This time Quinapril tablets are being pulled.
Read more »
Blood pressure tablets recalled over potential cancer risk, FDA announcesPatients who are on the medication don’t need to stop taking it immediately, but are advised to discuss an alternative treatment with their healthcare provider.
Read more »
U.S. FDA weighs regulating cannabis compound CBD in food, supplements - WSJThe U.S. Food and Drug Administration (FDA) is planning to make recommendations on how to regulate the use of popular cannabis compound CBD in food and supplements, the Wall Street Journal reported on Tuesday, citing agency officials.
Read more »
U.S. FDA weighs regulations on cannabis products in food and diet supplementsFDA officials tell the Wall Street Journal that safety concerns around CBD may cause the agency to publish its first guidelines on cannabis-derived products.
Read more »
U.S. FDA weighs regulating cannabis compound CBD in food, supplements - WSJAfter weighing the evidence on the compound's safety, the FDA will decide within months how to regulate legal cannabis and whether that will require new agency rules or new legislation from Congress, according to the report. Cannabis products, excluding Jazz Pharmaceuticals PLC's Epidiolex, are illegal at the federal level in the United States, although some states allow their use. The agency wants to know if CBD can be safely eaten every day for a long period or during pregnancy amid concerns about future fertility, Patrick Cournoyer, who heads the FDA office developing the agency's cannabis strategy, told WSJ.
Read more »